Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pandya

Showing results (161-170 of 188) with videos related to

Pageof 19
Sort By:
Investigational New Drugs|April 28, 2019
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumorsBin Fan, Ingo K Mellinghoff, Patrick Y Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell CarcinomaMartin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Scientific Reports|February 5, 2024
Elevated body temperature is associated with depressive symptoms: results from the TemPredict StudyAshley E Mason, Patrick Kasl, Severine Soltani, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|May 14, 2024
Feasibility and acceptability of an integrated mind-body intervention for depression: whole-body hyperthermia (WBH) and cognitive behavioral therapy (CBT)Ashley E Mason, Anoushka Chowdhary, Wendy Hartogensis, et al.
Scientific Reports|April 29, 2024
Author Correction: Elevated body temperature is associated with depressive symptoms: results from the TemPredict StudyAshley E Mason, Patrick Kasl, Severine Soltani, et al.
Investigational New Drugs|September 4, 2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumorsSuzanne F Jones, Lillian L Siu, Johanna C Bendell, et al.
The New England Journal of Medicine|April 20, 2022
Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid LeukemiaPau Montesinos, Christian Recher, Susana Vives, et al.
Nature Materials|February 16, 2016
Highly mobile ferroelastic domain walls in compositionally graded ferroelectric thin filmsJ C Agar, A R Damodaran, M B Okatan, et al.
American Journal of Hematology|June 24, 2023
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 studyCourtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2015
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced CancerGeoffrey I Shapiro, Katherine M Bell-McGuinn, Julian R Molina, et al.
Pageof 19

Showing results (161-170 of 188) with videos related to

Sort By:
Pageof 19
Investigational New Drugs|April 28, 2019
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumorsBin Fan, Ingo K Mellinghoff, Patrick Y Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell CarcinomaMartin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Scientific Reports|February 5, 2024
Elevated body temperature is associated with depressive symptoms: results from the TemPredict StudyAshley E Mason, Patrick Kasl, Severine Soltani, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|May 14, 2024
Feasibility and acceptability of an integrated mind-body intervention for depression: whole-body hyperthermia (WBH) and cognitive behavioral therapy (CBT)Ashley E Mason, Anoushka Chowdhary, Wendy Hartogensis, et al.
Scientific Reports|April 29, 2024
Author Correction: Elevated body temperature is associated with depressive symptoms: results from the TemPredict StudyAshley E Mason, Patrick Kasl, Severine Soltani, et al.
Investigational New Drugs|September 4, 2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumorsSuzanne F Jones, Lillian L Siu, Johanna C Bendell, et al.
The New England Journal of Medicine|April 20, 2022
Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid LeukemiaPau Montesinos, Christian Recher, Susana Vives, et al.
Nature Materials|February 16, 2016
Highly mobile ferroelastic domain walls in compositionally graded ferroelectric thin filmsJ C Agar, A R Damodaran, M B Okatan, et al.
American Journal of Hematology|June 24, 2023
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 studyCourtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2015
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced CancerGeoffrey I Shapiro, Katherine M Bell-McGuinn, Julian R Molina, et al.
Pageof 19